Date: Wednesday, August 16, 2023
Time: 11:00 AM ET / 10:00 AM CT / 8:00 AM PT / 3:00 PM GMT
Duration: 1 Hour
Already registered? Please click here to log in!
The potential of continuous processing methodologies to reduce variability while increasing efficiency, productivity and time-to-market are well proven in a range of industries—and has been proven to bring the same benefits to the pharmaceutical value chain. In this webinar, Dr. Malcolm Berry, recognized leader in developing continuous processes for small molecule active pharmaceutical ingredients (APIs) will discuss challenges with implementation, key observations, and Dr. Eric Edwards, CEO and Co-Founder of Phlow, will cover how continuous processing is helping Phlow Corp., a U.S.-based public benefit corporation to bring new levels of efficiency and quality to the organization’s contract development and manufacturing services, in turn helping pharmaceutical and biotech companies of all sizes reduce production costs, decrease development time, and lower their environmental impact.Speakers
Director and Founder, MB Chemistry Consulting Ltd.
Dr. Malcolm Berry is a recognized leader in the field of continuous processing for small molecules, whose work includes the development of the world’s first FDA- and EMA-approved multistage continuous production platform, as well as the lab-based technology and a workflow for developing continuous API processes. Dr. Berry has decades of experience working in the pharmaceutical industry as an organic chemist, including 26 years in process research and development in GlaxoSmithKline. He also has extensive experience working in research and development (R&D) pilot plants and leading the technical transfer of both new batch and continuous processes from R&D to manufacturing. In 2019, Dr. Berry left GlaxoSmithKline (GSK) and started a successful continuous API consulting practice that grew throughout the global pandemic. In 2022, Dr. Berry began a consulting partnership with Phlow Corp, a U.S.-based small molecule manufacturing solutions provider, as part of its CDMO program, called cdmoX, that is revolutionizing the way life-changing medicines are made.
Dr. Edwards was previously co-founder of Kaléo, Inc. a pharmaceutical company in Richmond, VA. During his 16 years at Kaléo, he held several executive management positions including Chief Science Officer where he was responsible for overall scientific strategy and all pharmaceutical development programs; Chief Medical Officer responsible for developing a medical affairs team and capability while operationalizing the Company’s clinical program strategy; and Vice President – Innovation, overseeing Kaleo’s research and development pipeline and overall new product strategy. Dr. Edwards is the co-inventor of multiple marketed products, including AUVI-Q, epinephrine auto-injector for the treatment of allergic emergencies (anaphylaxis), is named on over 215 issued and patent-pending applications, and is a published author on numerous scientific publications. Dr. Edwards also continues to serve his community by volunteering on a local rescue squad, including responding to 911 calls and training paramedics in pre-hospital emergency care. Dr. Edwards. obtained his B.S. in Biology, Ph.D. in the Pharmaceutical Sciences, and Doctor of Medicine degrees at Virginia Commonwealth University/Medical College of Virginia.Sponsored by: